Published in EMBO J on September 01, 1997
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev (1999) 4.39
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J (1998) 2.82
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med (1998) 2.11
Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 2.03
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol (2000) 1.80
Reovirus-induced apoptosis is mediated by TRAIL. J Virol (2000) 1.62
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett (2005) 1.53
Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest (2004) 1.52
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol (2005) 1.46
Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med (2001) 1.42
Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A (2003) 1.41
A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol (2005) 1.39
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol (2000) 1.35
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
Receptor-mediated choreography of life and death. J Clin Immunol (2003) 1.33
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci U S A (1999) 1.25
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol (2001) 1.24
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. BMC Genomics (2010) 1.20
Two functionally distinct forms of a retroviral receptor explain the nonreciprocal receptor interference among subgroups B, D, and E avian leukosis viruses. J Virol (2001) 1.20
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol (2003) 1.18
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
Parasporin, a human leukemic cell-recognizing parasporal protein of Bacillus thuringiensis. Clin Diagn Lab Immunol (2000) 1.15
Lyssavirus matrix protein induces apoptosis by a TRAIL-dependent mechanism involving caspase-8 activation. J Virol (2004) 1.14
Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J Exp Med (1998) 1.14
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm (2010) 1.10
Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal (2008) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Molecular mechanisms of neonatal brain injury. Neurol Res Int (2012) 1.07
A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses. J Virol (2002) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer (2010) 1.06
Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol Cell Biol (2007) 1.05
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ (2013) 1.04
Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 1.03
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell (2004) 1.03
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) (2009) 1.03
A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci U S A (1998) 1.03
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro Oncol (2011) 1.02
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation. J Biol Chem (2014) 1.02
The role of TRADD in death receptor signaling. Cell Cycle (2012) 1.00
Retracted Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol (2005) 1.00
Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol (2002) 0.99
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal (2007) 0.99
Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci U S A (2001) 0.98
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother (2008) 0.98
Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci (2010) 0.98
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol (2007) 0.96
The EMILIN/Multimerin family. Front Immunol (2012) 0.96
Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med (2012) 0.95
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer (2003) 0.95
ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res (2010) 0.95
HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol (2010) 0.95
Activated ERBB2/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-dependent pathway. Cancer Res (2014) 0.94
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal (2010) 0.94
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol (2006) 0.94
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood (2006) 0.94
Sp1-mediated TRAIL induction in chemosensitization. Cancer Res (2008) 0.94
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Mol Cancer Res (2011) 0.94
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem (2012) 0.93
Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget (2014) 0.93
Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells. Evid Based Complement Alternat Med (2013) 0.93
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One (2009) 0.92
Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87. World J Gastroenterol (2001) 0.92
Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem (2004) 0.91
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis (2000) 0.91
KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol (2011) 0.91
TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer (2003) 0.90
Genetic variation in APOJ, LPL, and TNFRSF10B affects plasma fatty acid distribution in Alaskan Eskimos. Am J Clin Nutr (2010) 0.89
The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. Cell Death Dis (2012) 0.89
JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation. Biochem J (2000) 0.89
The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Mol Med (2009) 0.89
Membrane trafficking of death receptors: implications on signalling. Int J Mol Sci (2013) 0.89
Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol (2003) 0.89
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells. Br J Cancer (2003) 0.88
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer (2011) 0.88
The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment. Neoplasia (2010) 0.88
DAPK2 is a novel modulator of TRAIL-induced apoptosis. Cell Death Differ (2014) 0.88
Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions. J Neuroimmunol (2007) 0.87
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Cell death: the significance of apoptosis. Int Rev Cytol (1980) 24.88
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature (1985) 9.94
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 8.80
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 7.52
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Analytical properties of the nanoelectrospray ion source. Anal Chem (1996) 7.12
Error-tolerant identification of peptides in sequence databases by peptide sequence tags. Anal Chem (1994) 7.04
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol (1993) 3.03
Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol (1994) 2.74
CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis. Cell (1996) 2.51
Appendix 5. Nomenclature for peptide fragment ions (positive ions). Methods Enzymol (1990) 2.41
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol (1996) 2.07
A death-domain-containing receptor that mediates apoptosis. Nature (1996) 1.92
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med (1997) 1.63
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ (1995) 1.32
From AIDS to parasite infection: pathogen-mediated subversion of programmed cell death as a mechanism for immune dysregulation. Immunol Rev (1994) 1.19
Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant (1988) 0.95
Suppression of tumorigenicity and invasiveness of colon carcinoma cells by introduction of normal chromosome 8p12-pter. Oncogene (1996) 0.89
Interferons: cytokines in autoimmunity. Ciba Found Symp (1987) 0.86
RAG-1-deficient mice have no mature B and T lymphocytes. Cell (1992) 20.97
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J (1998) 10.08
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
An essential role for ectodomain shedding in mammalian development. Science (1998) 9.14
Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93
DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell (1985) 7.62
Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science (1991) 7.25
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature (1994) 6.50
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res (2000) 6.14
DNA repair in bacteria and mammalian cells. Annu Rev Biochem (1979) 5.85
Mechanism of antigen-driven selection in germinal centres. Nature (1990) 5.26
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
Sequence heterogeneity in closed simian virus 40 deoxyribonucleic acid. J Virol (1972) 4.69
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science (1996) 4.61
Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev (2001) 4.45
Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34
Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol (2001) 4.03
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 3.83
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J (1999) 3.65
Bacteriophage and the toxigenicity of Clostridium botulinum type C. Science (1971) 3.63
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Molecular regulation of apoptosis: genetic controls on cell death. Cell (1993) 3.57
Incompatibility group P plasmids: genetics, evolution, and use in genetic manipulation. Annu Rev Microbiol (1987) 3.47
Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci U S A (1986) 3.42
Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev (2001) 3.39
Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol (1993) 3.29
Biology of HIF-1alpha. Cell Death Differ (2008) 3.24
A new cytokine receptor superfamily. Trends Biochem Sci (1990) 3.24
Patterns of cognitive appraisal in emotion. J Pers Soc Psychol (1985) 3.14
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol (1993) 3.03
Sequence database searches via de novo peptide sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom (1997) 3.03
c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an amino-truncated EGF receptor. Cell (1985) 3.00
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Are we vaccinating too much? J Am Vet Med Assoc (1995) 2.97
Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet (1996) 2.92
Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3. Proc Natl Acad Sci U S A (1986) 2.84
Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat Immunol (2001) 2.77
A lymphotoxin-beta-specific receptor. Science (1994) 2.73
Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell (2000) 2.70
Form C of the MHLC scales: a condition-specific measure of locus of control. J Pers Assess (1994) 2.69
The importance of timing: the varying impact of childhood and adolescent maltreatment on multiple problem outcomes. Dev Psychopathol (2001) 2.67
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity (1994) 2.59
Linkage scores and corrections in simple two- and three-generation families. Ann Hum Genet (1968) 2.52
Molecular cloning and characterization of retinal photoreceptor guanylyl cyclase-activating protein. Neuron (1994) 2.47
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
In vivo effects of intercalating drugs on the superhelix density of mitochondrial DNA isolated from human and mouse cells in culture. J Mol Biol (1971) 2.44
Long-term outcome in children after antenatal intervention for obstructive uropathies. Lancet (1999) 2.37
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Apoptosis: molecular regulation of cell death. Eur J Biochem (1996) 2.29
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med (1995) 2.28
Comparative analysis of binding of human damaged DNA-binding protein (XPE) and Escherichia coli damage recognition protein (UvrA) to the major ultraviolet photoproducts: T[c,s]T, T[t,s]T, T[6-4]T, and T[Dewar]T. J Biol Chem (1993) 2.28
Studies on the nature of the chloroplast lamella. I. Preparation and some properties of two chlorophyll-protein complexes. Biochemistry (1967) 2.25
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood (2001) 2.20
HOMOLOGOUS ANTIPNEUMOCOCCAL SERUMS IN THE TREATMENT OF LOBAR PNEUMONIA. Br Med J (1931) 2.20
Occurrence of complex mitochondrial DNA in normal tissues. Nature (1968) 2.18
The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest (1997) 2.18
Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A (1993) 2.18
A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 2.16
Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell (1993) 2.11
Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal Chem (1987) 2.10
Thymocyte selection is regulated by the helix-loop-helix inhibitor protein, Id3. Immunity (2000) 2.05
Implementation and uses of automated de novo peptide sequencing by tandem mass spectrometry. Anal Chem (2001) 2.05
Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res (1999) 2.05
Putting a price on biotechnology. Nat Biotechnol (2001) 2.01
Association of labial salivary gland histopathology with clinical and serologic features of connective tissue diseases. Arthritis Rheum (1990) 1.99
Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A (1997) 1.97
Small polydisperse circular DNA of HeLa cells. J Mol Biol (1972) 1.96
Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol (2000) 1.95
Sensitive determination of pyrimidine dimers in DNA of UV-irradiated mammalian cells. Introduction of T4 endonuclease V into frozen and thawed cells. Mutat Res (1981) 1.90
Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect (2001) 1.90
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem (1996) 1.89
SOME PROPERTIES OF HUMAN FETAL AND MATERNAL BLOOD. J Clin Invest (1941) 1.86